ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
Скачать

Demystifying the Investigational New Drug (IND) Application for Drugs and Biologics (3of14) REdI '18

REdI

CDER

FDA

SBIA

Автор: U.S. Food and Drug Administration

Загружено: 2020-05-15

Просмотров: 5899

Описание: CDER’s Kevin Bugin provides a brief history of the regulations behind Investigational New Drug (IND) applications. He shares an introduction to INDs, including what the application is and role of the application in the regulation of clinical research for new drugs and biological products. Bugin shares when the application is needed, the different categories and types of applications, and policy on jurisdiction and bundling. Finally, the presentation will share information on the pre-IND consultation program.
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming training and free continuing education credits: https://www.fda.gov/cdersbia

CDER SBIA 2018 Playlist:    • 2018 CDER Small Business and Industry Assi...  
LinkedIn:   / cder-small-business-and-industry-assistance  
Training resources: https://www.fda.gov/cderbsbialearn

Twitter:   / fda_drug_info  

CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
Demystifying the Investigational New Drug (IND) Application for Drugs and Biologics (3of14) REdI '18

Поделиться в:

Доступные форматы для скачивания:

Скачать видео

  • Информация по загрузке:

Скачать аудио

Похожие видео

Formal Meetings for PDUFA Products and Communication Best Practices (4of14) REdI 2018

Formal Meetings for PDUFA Products and Communication Best Practices (4of14) REdI 2018

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017

Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Expert Panel on Testosterone Replacement Therapy for Men

Introduction to Investigational New Drug (IND) Applications (3/14) REdI 2017

Introduction to Investigational New Drug (IND) Applications (3/14) REdI 2017

Why Does The FDA Exist?

Why Does The FDA Exist?

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

Getting to First-in-Human for Small Molecules and Biologics

Getting to First-in-Human for Small Molecules and Biologics

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

503B Product Reporting for Compounding Outsourcing Facilities (7/7) Drug Registration & Listing 2018

503B Product Reporting for Compounding Outsourcing Facilities (7/7) Drug Registration & Listing 2018

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

The Basics of Biosimilars

The Basics of Biosimilars

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

CMC Considerations for Biotechnology Product Development: A Regulatory Perspective

CMC Considerations for Biotechnology Product Development: A Regulatory Perspective

Study Data Submissions: Office of Vaccines Research and Review (OVRR) Data Submission – May 8, 2018

Study Data Submissions: Office of Vaccines Research and Review (OVRR) Data Submission – May 8, 2018

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]